INAMRINONE LACTATE

Details

Stereochemistry	UNKNOWN
Molecular Formula	C10H9N3O.C3H6O3
Molecular Weight	277.2759
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0
Stereo Comments	LACTATE

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)C(O)=O.NC1=CC(=CNC1=O)C2=CC=NC=C2

InChI

InChIKey=DOSIONJFGDSKCQ-UHFFFAOYSA-N

InChI=1S/C10H9N3O.C3H6O3/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7;1-2(4)3(5)6/h1-6H,11H2,(H,13,14);2,4H,1H3,(H,5,6)

HIDE SMILES / InChI

Molecular Formula	C3H6O3
Molecular Weight	90.0779
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	C10H9N3O
Molecular Weight	187.198
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB01427
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/inamrinone.html

Inamrinone (Amrinone) is a positive inotropic cardiotonic with vasodilator properties, phosphodiesterase inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell. Inamrinone is a phosphodiesterase inhibitor (PDE3), resulting in increased cAMP and cGMP which leads to an increase in the calcium influx like that caused by beta-agonists resulting in increased inotropic effect. Inamrinone is used in the treatment of congestive heart failure.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Phosphodiesterase 3A 7 Target ID: CHEMBL241 Sources: http://www.drugbank.ca/drugs/DB01427	Inhibitor 8297	16.7 µM [IC50]
Phosphodiesterase 3B 8 Target ID: CHEMBL290 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10644042	Inhibitor 8297	31.2 µM [IC50]
platelet aggregation 76 Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14698653	Inhibitor 8297	61.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Congestive heart failure 54 Sources: https://www.drugs.com/pro/inamrinone.html	Primary		Approved 8429	AMRINONE LACTATE Approved Use For the short-term management of congestive heart failure. Launch Date 2000

C_max

Value	Dose	Co-administered	Analyte	Population
5.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513658/	0.75 mg/kg 3 times / day steady-state, intravenous dose: 0.75 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		INAMRINONE plasma	Homo sapiens population: UNKNOWN age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
245 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513658/	0.75 mg/kg 3 times / day steady-state, intravenous dose: 0.75 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		INAMRINONE plasma	Homo sapiens population: UNKNOWN age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513658/	0.75 mg/kg 3 times / day steady-state, intravenous dose: 0.75 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		INAMRINONE plasma	Homo sapiens population: UNKNOWN age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
198 ug/kg/min 1 times / day single, intravenous (max) Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 n = 1 Health Status: unhealthy Condition: heart failure Age Group: 0.208333333333333 Sex: F Population Size: 1 Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	Other AEs: Cardiac arrest... Other AEs: Cardiac arrest Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
198 ug/kg/min 1 times / day single, intravenous (max) Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 n = 1 Health Status: unhealthy Condition: heart failure Age Group: 0.208333333333333 Sex: F Population Size: 1 Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	Other AEs: Death... Other AEs: Death (grade 5) Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	Disc. AE: Pulmonary edema, Cardiac arrest... AEs leading to discontinuation/dose reduction: Pulmonary edema Cardiac arrest Respiratory distress syndrome Chest pain Palpitations Ventricular ectopic beats Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
200 mg 3 times / day multiple, oral Highest studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	unhealthy, 53 n = 32 Health Status: unhealthy Condition: congestive heart failure Age Group: 53 Sex: M+F Population Size: 32 Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	Disc. AE: Diarrhea, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Diarrhea Thrombocytopenia Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/
5.8 mg/kg/day 1 times / day multiple, intravenous (mean) Recommended Dose: 5.8 mg/kg/day, 1 times / day Route: intravenous Route: multiple Dose: 5.8 mg/kg/day, 1 times / day Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456	unhealthy, 59.4 (37-81) n = 43 Health Status: unhealthy Condition: congestive heart failure Age Group: 59.4 (37-81) Sex: M+F Population Size: 43 Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456	Disc. AE: Thrombocytopenia... AEs leading to discontinuation/dose reduction: Thrombocytopenia (18.6%) Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456
3 mg/kg 1 times / day single, intravenous (max) Recommended Dose: 3 mg/kg, 1 times / day Route: intravenous Route: single Dose: 3 mg/kg, 1 times / day Sources: https://www.nature.com/articles/pr1984440	unhealthy, <1 n = 6 Health Status: unhealthy Condition: pulmonary hypertension Age Group: <1 Sex: M+F Population Size: 6 Sources: https://www.nature.com/articles/pr1984440	Sources: https://www.nature.com/articles/pr1984440

AEs

AE	Significance	Dose	Population
Cardiac arrest		198 ug/kg/min 1 times / day single, intravenous (max) Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 n = 1 Health Status: unhealthy Condition: heart failure Age Group: 0.208333333333333 Sex: F Population Size: 1 Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
Death	grade 5	198 ug/kg/min 1 times / day single, intravenous (max) Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 n = 1 Health Status: unhealthy Condition: heart failure Age Group: 0.208333333333333 Sex: F Population Size: 1 Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
Cardiac arrest	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Chest pain	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Palpitations	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Pulmonary edema	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Respiratory distress syndrome	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Ventricular ectopic beats	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Diarrhea	Disc. AE	200 mg 3 times / day multiple, oral Highest studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	unhealthy, 53 n = 32 Health Status: unhealthy Condition: congestive heart failure Age Group: 53 Sex: M+F Population Size: 32 Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/
Thrombocytopenia	Disc. AE	200 mg 3 times / day multiple, oral Highest studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	unhealthy, 53 n = 32 Health Status: unhealthy Condition: congestive heart failure Age Group: 53 Sex: M+F Population Size: 32 Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/
Thrombocytopenia	18.6% Disc. AE	5.8 mg/kg/day 1 times / day multiple, intravenous (mean) Recommended Dose: 5.8 mg/kg/day, 1 times / day Route: intravenous Route: multiple Dose: 5.8 mg/kg/day, 1 times / day Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456	unhealthy, 59.4 (37-81) n = 43 Health Status: unhealthy Condition: congestive heart failure Age Group: 59.4 (37-81) Sex: M+F Population Size: 43 Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-0633	http://www.3bsc.com/index/pro_info.php?id=19989
3B Scientific (Wuhan) Corp	3B1-00216	http://www.3bsc.com/index/pro_info.php?id=20428
AEchem Scientific Corp., USA	AE044729	http://www.aechemsc.com/info_products/AE044729.php
AHH Chemical co.,ltd	API-1603	http://www.ahhchemical.com/product/API-1603.html
AHH Chemical co.,ltd	MT-00030	http://www.ahhchemical.com/product/MT-00030.html
AK Scientific, Inc. (AKSCI)	868269	http://www.aksci.com/item_detail.php?cat=868269
Acadechem	ACDS-033154	http://www.acadechemical.com/product/107853
Achemo Scientific Limited	AC-16677	http://www.achemo.com/search/?Keyword= 60719-84-8
Achemtek	0104-017105	http://www.achemtek.com/60719-84-8
Alfa Chemistry	AP60719848	https://reagents.alfa-chemistry.com/product/amrinone-cas-60719-84-8-13957.html
Alichem	22004023	http://www.alichem.com/en/products/216151-27-8.html
Allbio Pharm Co., Ltd	AD03248	http://www.allbiopharm.com/product/n/AD03248
Ambinter	Amb18649580	http://www.ambinter.com/reference/18649580
Angel Pharmatech	AG337888	http://www.angelpharmatech.com/60719-84-8.html
Angene	AGN-PC-0JK6MN	http://www.angenechemical.com/productshow/AGN-PC-0JK6MN.html
Anward	ANW-56874	http://www.anward.com/pro_result/43325
Ark Pharm	AK-99994	http://www.arkpharminc.com/products/60719-84-8.html
Aurora Fine Chemicals LLC	A02.558.326	http://online.aurorafinechemicals.com/info?ID=A02.558.326
Aurum Pharmatech LLC	M-2461	http://www.Aurumpharmatech.com/Product/ProductDetails/M_2461
Avantor Inc	101094-302	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101094-302
Avantor Inc	101096-786	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101096-786
BLD Pharm	BD12830	http://www.bldpharm.com/products/60719-84-8.html
BioChemPartner	BCP12764	http://www.biochempartner.com/60719-84-8-BCP12764
BioSynth	W-105234	https://www.biosynth.com/en/products/life-science/enzyme-substrates-reagents/products/W-105234.html
CSNpharm	CSN10951	https://www.csnpharm.com/products/amrinone.html
Chem Scene	CS-0013064	http://www.chemscene.com/60719-84-8.html
ChemMol	30101988	http://www.chemmol.com/chemmol/30101988.html
ChemMol	49424520	http://www.chemmol.com/chemmol/49424520.html
Chemspace	CSSB00000063426	https://chem-space.com/CSSB00000063426
Clearsynth	CS-T-03714	https://www.clearsynth.com/en/CST03714.html
Combi-Blocks	QA-1160	http://www.combi-blocks.com/cgi-bin/find.cgi?QA-1160
DC Chemicals	DC8957	http://www.dcchemicals.com/product_show-Amrinone.html
Finetech	FT-0601595	http://www.finetechnology-ind.com/prod/detail/pub/60719-84-8.html
Glentham Life Sciences	GP7331	http://www.glentham.com/products/product/GP7331/
Hairui	HR132658	http://www.hairuichem.com/en/product/60719-84-8.html
Lab Network	LN00194482	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00194482
MedChem Express	HY-B1294	https://www.medchemexpress.com/amrinone.html
OChem	822	http://www.ocheminc.com/index.php?act=psearch&pid=719A848
Sigma-Aldrich	A4056_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a4056?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1034308_USP	https://www.sigmaaldrich.com/catalog/product/usp/1034308?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S017497	http://www.sinfoobiotech.com/product/1020895
Smolecule	S518817	http://www.smolecule.com/products/s518817
THE BioTek	bt-259866	https://www.thebiotek.com/product/inhibitors/bt-259866
eNovation Chemicals	D673798	https://www.enovationchem.com/ProductDetails.asp?ProductID=D673798
eNovation Chemicals	D765978	https://www.enovationchem.com/ProductDetails.asp?ProductID=D765978
eNovation Chemicals	D961064	https://www.enovationchem.com/ProductDetails.asp?ProductID=D961064
mcule	MCULE-2781267039	https://mcule.com/MCULE-2781267039/

PubMed

Title	Date	PubMed
Amrinone for refractory cardiogenic shock following chloroquine poisoning.	1991	1774400
Reversal of propranolol blockade of adrenergic receptors and related toxicity with drugs that increase cyclic AMP.	1999 Sep	10460701
Lack of role for nitric oxide in cholinergic modulation of myocardial contractility in vivo.	2001 Jul	11406486
Amrinone can accelerate the cooling rate of core temperature during deliberate mild hypothermia for neurosurgical procedures.	2001 May	11575342
Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids.	2002	11969359
Role of cyclic nucleotides in ischemia and reperfusion injury of canine livers.	2002 Apr 15	11965029
The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis.	2002 Aug	12167393
Immunopharmacological potential of selective phosphodiesterase inhibition. II. Evidence for the involvement of an inhibitory-kappaB/nuclear factor-kappaB-sensitive pathway in alveolar epithelial cells.	2002 Feb	11805218
The efficacy of preemptive Milrinone or Amrinone therapy in patients undergoing coronary artery bypass grafting.	2002 Jan	11772795
Effects of amrinone on hepatic ischemia-reperfusion injury in rats.	2002 Jul	12076859
PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels.	2002 Jun	12034568
Cardiovascular effects of a phosphodiesterase III inhibitor, amrinone, in infants: non-invasive echocardiographic evaluation.	2002 Jun	11982892
Effects of cAMP modulators on long-chain fatty-acid uptake and utilization by electrically stimulated rat cardiac myocytes.	2002 Nov 1	12093365
Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase.	2002 Oct	12356583
Differential effects of amrinone and milrinone upon myocardial inflammatory signaling.	2002 Sep 24	12354747
Effects of epinephrine and phosphodiesterase III inhibitors on bupivacaine-induced myocardial depression in guinea-pig papillary muscle.	2003 Jan	12488382
Inhibition and facilitation by pimobendan, a calcium sensitizer, of catecholamine secretion from bovine adrenal chromaffin cells.	2003 Mar	12686744
Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin.	2003 Oct	14577594
Successful allogeneic bone marrow transplantation for acute myelogenous leukemia after drug-induced cardiomyopathy.	2004 Sep	15329467
Meta-analysis of hemodynamic optimization: relationship to methodological quality.	2005	16356226
Phosphodiesterase-III-inhibition with amrinone leads to contracture development in skeletal muscle preparations of malignant hyperthermia susceptible swine.	2005 Apr	15892406
Effects of a phosphodiesterase 3 inhibitor, olprinone, on rhythmical change in tension of human gastroepiploic artery.	2005 Dec 28	16325808
SCH00013, a novel Ca(2+) sensitizer with positive inotropic and no chronotropic action in heart failure.	2005 Jan	15644593
Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery -- a systematic literature review.	2005 Jun	15987381
Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats.	2005 May 9	15910807
Bench-to-bedside review: hyperinsulinaemia/euglycaemia therapy in the management of overdose of calcium-channel blockers.	2006	16732893
Alkaline Phosphatases : Structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes.	2006 Jun	18404473
Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers.	2006 Oct 1	16990629
Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity.	2007 Jan-Feb	17146843
Peripartum cardiomyopathy: review of the literature.	2007 Oct 31	17963329
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.	2008 Jan	18058085
Effect of nitric oxide/cyclic guanosine mono-phosphate pathway on gallbladder relaxant response in bile duct-ligated guinea pigs.	2009	19246926
Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates.	2009 Jan	18930951
Evaluation of preoperative intra-aortic balloon pump in coronary patients with severe left ventricular dysfunction undergoing OPCAB surgery: early and mid-term outcomes.	2009 Jul 27	19635155

Patents

Sample Use Guides

In Vivo Use Guide

Congestive heart failure IV Initially, 0.75 mg/kg as a slow (over 2–3 minutes) direct injection; if warranted, may administer a supplemental direct IV dose of 0.75 mg/kg 30 minutes after the initial dose.1 60 Direct IV injection is followed by an IV infusion of 5–10 mcg/kg per minute. Duration of therapy determined by clinical response and tolerance to adverse effects.

Route of Administration: Intravenous

In Vitro Use Guide

Inamrinone inhibited human platelet aggregation at 10,800 s(-1) in a dose-dependent manner with the IC(50) value of 61 +/- 8 uM (mean +/- S.D.), Inamrinone significantly inhibited platelet aggregation at 1200 s(-1) only at highest concentration tested (100 uM)

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:21:23 GMT 2023` Edited by `admin` on `Fri Dec 15 16:21:23 GMT 2023`
Record UNII	I229274Y5B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

INAMRINONE LACTATE

Common Name

English

Amrinone lactate [WHO-DD]

Common Name

English

INOCOR

Brand Name

English

INAMRINONE LACTATE [ORANGE BOOK]

Common Name

English

PROPANOIC ACID, 3-HYDROXY-, COMPD. WITH 5-AMINO(3,4'-BIPYRIDIN)-6(1H)-ONE

Common Name

English

INAMRINONE LACTATE [VANDF]

Common Name

English

5-AMINO(3,4'-BIPYRIDIN)-6(1H)-ONE LACTATE

Systematic Name

English

AMRINONE LACTATE [MART.]

Common Name

English

AMRINONE LACTATE

Common Name

English

AMRINONE LACTATE [VANDF]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C744